Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin.

Objectives: To define predictive parameters of long progression-free survival (PFS) in patients undergoing radioembolisation of neuroendocrine liver metastases.Methods: The following clinical and magnetic resonance imaging (MRI) parameters of 45 radioembolised patients (median age, 62 years; range,...

Descripción completa

Detalles Bibliográficos
Publicado en:European Radiology Vol. 23; no. 11; pp. 3094 - 3104
Autores principales: Sommer, Wieland H, Ceelen, Felix, García-Albéniz, Xabier, Paprottka, Philipp M, Auernhammer, Christoph J, Armbruster, Marco, Nikolaou, Konstantin, Haug, Alexander R, Reiser, Maximilian F, Theisen, Daniel
Formato: research Journal Article
Publicado: Springer Nature Nov2013
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104103283&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104103283
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09387994
        NPH
      jtl: European Radiology
      issn: 09387994
      maglogo: N
    pubinfo:
      dt: Nov2013
      vid: 23
      iid: 11
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        104103283
        NLM23807569
        2012337703
        10.1007/s00330-013-2925-8
        NLM23807569
        104103283
      ppf: 3094
      ppct: 10
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin.
      aug:
        au:
          Sommer, Wieland H
          Ceelen, Felix
          García-Albéniz, Xabier
          Paprottka, Philipp M
          Auernhammer, Christoph J
          Armbruster, Marco
          Nikolaou, Konstantin
          Haug, Alexander R
          Reiser, Maximilian F
          Theisen, Daniel
        affil: Department of Clinical Radiology, University Hospitals-Grosshadern, Ludwig-Maximilians University, Munich, Germany, wieland.sommer@med.uni-muenchen.de.
      sug:
        subj:
          Antineoplastic Agents Therapeutic Use
          Liver Neoplasms Therapy
          Magnetic Resonance Imaging Methods
          Neuroendocrine Tumors Therapy
          Adult
          Aged
          Chemoembolization, Therapeutic Methods
          Prognosis
          Female
          Prospective Studies
          Human
          Liver Neoplasms Diagnosis
          Liver Neoplasms
          Male
          Latex
          Middle Age
          Neuroendocrine Tumors Diagnosis
          Neuroendocrine Tumors
          Retrospective Design
          Treatment Outcomes
          Adult: 19-44 years
          Aged: 65+ years
          Middle Aged: 45-64 years
          Female
          Male
      ab: Objectives: To define predictive parameters of long progression-free survival (PFS) in patients undergoing radioembolisation of neuroendocrine liver metastases.Methods: The following clinical and magnetic resonance imaging (MRI) parameters of 45 radioembolised patients (median age, 62 years; range, 43-75) were reviewed: age, gender, levels of chromogranin A and neuron-specific enolase (NSE), primary tumour site, Ki-67 proliferation index, hepatic tumour load, number of metastases, signal intensity characteristics, vascularisation, haemorrhagic and necrotic transformation and fluid-fluid levels. PFS was assessed according to RECIST 1.0. Statistical analysis included univariate Cox regression, Kaplan-Meier and multivariate regression.Results: Median PFS was 727 days (95 % CI, 378-964). In the univariate regression analysis, hypovascular metastases progressed earlier (111 vs 727 days; P < 0.05). A Ki-67 ≤2 % was associated with a longer PFS than a Ki-67 of 3-20 % or >20 % (911 vs 727 vs 210 days, respectively; P < 0.05). Low NSE predicted longer PFS (911 vs 378 days; P < 0.05). In the adjusted multivariate analysis, vascularisation (hypervascularisation vs. no hypervascularisation; P = 0.0009) and NSE level (low vs high; P = 0.0119) had the strongest influence on PFS.Conclusion: Response to radioembolisation in patients with neuroendocrine liver metastases can be predicted by the metastatic vascularisation pattern, the NSE level and the Ki-67.Key Points: • Radioembolisation is an effective treatment in hepatic metastases of neuroendocrine origin. • Pre-therapeutic vascularisation patterns of metastases on MRI can predict long progression-free survival. • Assessment of pre-therapeutic markers provides better therapy planning.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N